Background And Objective: Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.

Methods: Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity and specificity for asthma diagnosis. Response-dose ratio was also compared.

Results: A total of 50 asthmatic adults and 54 controls were enrolled (mean age 43.8 years). The sensitivity and specificity of mannitol challenge (defined by a PD15 of <635 mg) were 48.0% and 92.6%, respectively, whereas those of methacholine (defined by a PC20 of <16 mg/mL) were 42.0% and 98.1%, respectively. Twenty asthmatic participants (24%) showed positive response to a single agonist only. In the receiver operating curve analyses using response-dose ratio values, area under the curve was 0.77 (95% confidence interval (CI): 0.68-0.86) for mannitol, and 0.89 (95% CI: 0.83-0.95) for methacholine. The correlations between log- transformed mannitol and methacholine response-dose ratios were significant but moderate (r = 0.683, P < 0.001).

Conclusions: The present study demonstrated overall similar diagnostic properties of two diagnostic tests, but also suggested their intercomplementary roles for asthma. The clinical trial registration number at ClinicalTrial.gov is NCT02104284.

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.12334DOI Listing

Publication Analysis

Top Keywords

methacholine mannitol
16
diagnostic properties
12
properties methacholine
8
mannitol bronchial
8
bronchial challenge
8
sensitivity specificity
8
mannitol
5
diagnostic
4
methacholine
4
challenge tests
4

Similar Publications

Background: Considerable variability exists between asthma diagnostic guidelines. We tested the performance characteristics of the European Respiratory Society (ERS), the National Institute for Health and Care Excellence (NICE) and the Global Initiative for Asthma (GINA) guidelines for the diagnosis of asthma in adults.

Methods: In this prospective observational study (ISRCTN-11676160, May 2019-June 2022), participants referred from primary care with clinician-suspected asthma underwent comprehensive investigation including: spirometry, bronchodilator reversibility, fractional exhaled nitric oxide, peak expiratory flow variability, bronchial challenge testing with methacholine and mannitol, and responsiveness to inhaled corticosteroid therapy.

View Article and Find Full Text PDF

Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review.

J Asthma Allergy

July 2023

Division of Pulmonary, Critical Care and Sleep Medicine, and the Center for Lung Biology, Department of Medicine, University of Washington, Seattle, WA, USA.

Article Synopsis
  • Airway hyperresponsiveness (AHR) is a key feature of asthma, and biologic therapies target specific parts of the inflammatory pathway, which can help understand asthma better.
  • This review systematically assessed studies from 1997 to 2021 to evaluate the effects of various biologics on AHR, early allergic response (EAR), and late allergic response (LAR) in asthma patients.
  • Findings revealed that Omalizumab and Tezepelumab effectively reduced EAR, LAR, and AHR, while other biologics like Mepolizumab and several others showed little to no impact on AHR or allergic responses.*
View Article and Find Full Text PDF

Impact of airway challenges on cardiovascular risk in asthma - a randomized controlled trial.

PLoS One

July 2023

Pulmonary Division, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Background: People experiencing asthma exacerbations are at increased risk of cardiovascular events. To better understand the relationship between asthma exacerbations and cardiovascular risk, this randomized case-control, cross-over controlled trial assessed the immediate systemic inflammatory and vascular responses to acutely induced pulmonary inflammation and bronchoconstriction in people with asthma and controls.

Methods: Twenty-six people with asthma and 25 controls underwent three airway challenges (placebo, mannitol, and methacholine) in random order.

View Article and Find Full Text PDF

Introduction: The role of bronchial provocation tests in the diagnosis of asthma remains to be fully explored. We aimed to evaluate methacholine and mannitol challenge testing, and explore the factors associated with this broncoprovocation response.

Methods: Observational, cross-over, randomized trial evaluating adult cases with suspected asthma, naïve to treatment, with normal pre-bronchodilator spirometry, and negative bronchodilator test.

View Article and Find Full Text PDF

Allergen provocation tests in respiratory research: building on 50 years of experience.

Eur Respir J

August 2022

Dept of Microbiology Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Article Synopsis
  • The allergen provocation test helps scientists understand how things like pollen and dust can make people with allergies or asthma feel sick in their lungs and nose.
  • It studies early reactions in the upper airways and late reactions in the lower airways, which helps researchers develop new medicines for asthma.
  • Recent advancements in research are helping to create more personalized treatments by looking at different types of asthma and better ways to test lung function.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!